Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Malinowska, Izabela A ^a   Lee, Nancy ^a   Kumar, Vidhya ^a   Thiele, Elizabeth A ^b   Franz, David Neal ^c   Ashwal, Stephen ^d   Sagalowsky, Arthur ^e   DiMario, Francis J ^f   Cutler, Drew ^d   Krueger, Darcy ^c   Camposano, Susana ^b   Paolini, Jan ^b   Dabora, Sandra L ^a,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Division of Pediatric Infectious Diseases   (United States)

^g East Boston Neighborhood Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; VASCULOTROPIN D;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY HEMANGIOMYOLIPOMA; LEUKOPENIA; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; MULTICENTER STUDY; NEUTROPENIA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PROTEINURIA; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR VOLUME; UNITED STATES; WEIGHT GAIN;

EID: 84874243150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056199     Document Type: Article

References (29)

1. Tammela T, Alitalo K, (2010) Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
2. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J, (2009) Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 135: 1293-1300.
3. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, et al. (2006) Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 4: 143-152.
4. Young LR, Inoue Y, McCormack FX, (2008) Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 358: 199-200.
5. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP, (2007) Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36: 398-408.
6. Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, et al. (2010) Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138: 674-681.
7. Carsillo T, Astrinidis A, Henske EP, (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97: 6085-6090.
8. Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, et al. (1995) Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 13: 295-298.
9. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, et al. (1996) Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 59: 400-406.
10. Hirama M, Atsuta R, Mitani K, Kumasaka T, Gunji Y, et al. (2007) Lymphangioleiomyomatosis diagnosed by immunocytochemical and genetic analysis of lymphangioleiomyomatosis cell clusters found in chylous pleural effusion. Intern Med 46: 1593-1596.
11. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, et al. (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62: 810-815.
12. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, et al. (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277: 30958-30967.
13. Marcotte L, Crino PB, (2006) The neurobiology of the tuberous sclerosis complex. Neuromolecular Med 8: 531-546.
14. Roach ES, Gomez MR, Northrup H, (1998) Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 13: 624-628.
15. Costello LC, Hartman TE, Ryu JH, (2000) High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 75: 591-594.
16. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, et al. (2001) Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 164: 661-668.
17. Crino PB, Nathanson KL, Henske EP, (2006) The tuberous sclerosis complex. N Engl J Med 355: 1345-1356.
18. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151.
19. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, et al. (2011) Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One 6: e23379.
20. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, et al. (2011) Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 trial. Clin Cancer Res 17: 4071-4081.
21. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New England Journal of Medicine 363: 1801-1811.
22. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, et al. (2011) Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. N Engl J Med 364: 1595-1606.
23. Therasse P, (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
24. Motulsky H (2003) Fitting Models to Biological Data using Linear and Nonlinear Regression. GraphPad Software, Inc, San Diego, CA.
25. Issaka RB, Oommen S, Gupta SK, Liu G, Myers JL, et al. (2009) Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol 175: 1410-1420.
26. Seyama K, Mitani K, Kumasaka T, Gupta SK, Oommen S, et al. (2010) Lymphangioleiomyoma cells and lymphatic endothelial cells: expression of VEGFR-3 in lymphangioleiomyoma cell clusters. Am J Pathol 176: 2051-2052; author reply 2052-2054.
27. Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, et al. (2008) VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13: 554-556.
28. Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K, et al. (2001) Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 193: 147-154.
29. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, et al. (2009) Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 18: 894-900.